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Background: Salla disease (SD) is a rare lysosomal storage disorder leading to severe intellectual disability. SD
belongs to the Finnish disease heritage, and it is caused by mutations in the SLC17A5 gene. The aim of the study
was to investigate the course of neurocognitive features of SD patients in a long-term follow-up.
Methods: Neuropsychological and neurological investigations were carried out on 24 SD patients, aged 16–65
years, 13 years after a similar examination.
Results: The survival analysis showed excess mortality among patients with SD after the age of 30 years. The
course of the disease was progressive, but follow-up of SD patients revealed that motor skills improved till the age
of 20 years, while mental abilities improved in most patients till 40 years of age. Verbal comprehension skills did not
diminish during the follow-up, but productive speech deteriorated because of dyspraxia and dysarthria. Motor
deficits were marked. Ataxia was prominent in childhood, but it was replaced by athetotic movements during the
teens. Spasticity became more obvious with age especially in severely disabled SD patients.
Conclusions: Younger SD patients performed better in almost every task measuring mental abilities that then seem
to remain fairly constant till early sixties. Thus, the results indicate better prognosis in cognitive skills than earlier
assumed. There is an apparent decline in motor skills after the age of 20 years. The early neurocognitive
development predicts the later course of motor and cognitive development.
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Salla disease (SD; OMIM 604369) is a rare lysosomal
storage disease that belongs to the Finnish disease heri-
tage [1–3]. SD is caused by mutations in the SLC17A5
gene encoding a protein, sialin that is responsible for si-
alic acid transport across lysosomal membranes and that
is required for normal CNS myelination [4]. The preva-
lence of the major founder mutation, R39C (SallaFIN
mutation), is high in the northeast of Finland, where
founder effect contributes to the high carrier frequency
of 1:100 [5, 6]. Most Finnish SD patients are homozy-
gous for the R39C mutation [6], while a few patients are
compound heterozygotes harboring this SallaFIN muta-
tion and another SLC17A5 mutation. The phenotype of* Correspondence: liisa.paavola@neural.fi
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severe than that in patients with homozygous mutations
[6, 7]. The severe phenotype is characterized by young
age at onset of neurodevelopmental symptoms, motor
retardation, cerebral dysmyelination, cerebral and cere-
bellar atrophy, as well as peripheral nerve involvement
[7, 8]. Mutations in the SLC17A5 gene cause also infant-
ile sialic acid storage disease (ISSD; OMIM 269920) that
represents the most severe form of lysosomal free sialic
acid diseases [9, 10]. The children are severely affected
already in utero or the first signs of the disease appear
immediately after birth [6, 11, 12], and they usually sur-
vive less than 2 years. Mutations found in these patients
are different from those in SD patients.
The first symptoms of SD include nystagmus, muscu-
lar hypotonia, ataxia, and delayed motor development
[2, 7, 13], and they are usually noticed at the age of 3–12
months. All patients become intellectually disabled, but
life expectancy is only slightly decreased [2]. Epilepsy isrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Paavola et al. Journal of Neurodevelopmental Disorders  (2015) 7:20 Page 2 of 7a common symptom. On the basis of disease severity,
a conventional and a severe phenotype of SD have
been defined [7]. In addition, a few patients have
been reported with relatively mild symptoms [7, 14].
Cerebral and cerebellar atrophy, dysmyelination, and
corpus callosum hypoplasia are typical for all patients
with SD [15–17].
Motor handicap in SD begins to develop in early in-
fancy, and the decline in motor skills is more pro-
nounced than that in cognition after the second decade
of life. We have previously carried out a cross-sectional
study on neurological findings and neurocognitive pro-
file in 41 Finnish SD patients [7, 18]. Motor disability
was severe in these patients, and the characteristic cog-
nitive profile consisted of spatial and visual constructive
impairments. Interestingly, the interactive and non-
verbal communication skills were quite strong. Here we
describe results from a longitudinal study on changes in
neurocognitive findings during a 13-year follow-up of 24
Finnish SD patients. We found that the course of the
disease was progressive, but follow-up of SD patients re-
vealed that motor skills improved till the age of 20 years,




Forty-one patients with SD were examined in our previ-
ous study [18]. Eight patients (six women) had died after
this baseline study, six patients (one woman) declined
to participate, and three patients (two women) were
excluded, because they had not been evaluated with the
Bayley Scales of Infant Development (BSID-II) at base-
line. The subjects of the follow-up study thus comprised
of 24 SD patients (nine women) that were examined 13
years after the baseline study. Nineteen patients were
homozygous for the SallaFIN mutation, and five were
compound heterozygotes.
The study was approved by the Ethics Committee of
Oulu University Hospital. The written informed consent
was obtained from the patients and their caregivers.Table 1 Methods of neuropsychological evaluation
Abbreviation Full name of test
BSID-II Bayley Scales of Infant Development 2nd ed.
NEPSY Children’s Neuropsychological Test Battery (3–6 y
PANESS Physical and Neurological Examination for Soft Si
Cerebellar tests Static and dynamic cerebellar tests
TUG test Timed Up and Go testProcedure
The patients were examined by the same neuropsycholo-
gist and, with two exceptions, by the same neurologist.
BSID-II was used to measure the mental and motor
development [19] at the follow-up visit (Table 1), and
results from BSID-II at the baseline were available for
comparison. Developmental age (DA), a measure of a
child’s cognitive and motor development expressed in
terms of age norms, was also evaluated. The raw scores
from the mental and motor tasks of BSID-II were aggre-
gated into respective sum variables, and the achievement
of each patient was defined as a percentage of the max-
imum of the sum variable. The phenotype was further
characterized by using the verbal subtests of NEPSY
(Children’s Neuropsychological Test Battery) [17, 20],
the PANESS test (Physical and Neurological Examin-
ation for Soft Signs) [21, 22], the TUG test (Timed Up
and Go test) [23], and cerebellar tests [24].Survival analysis
A survival analysis was performed on the 41 patients
with SD who had participated in the baseline study.
Kaplan-Meier survival analysis and log-rank statistics
were used to compare the observed lifetimes of the pa-
tients with their life expectancies at birth. The life expect-
ancies were obtained from statistics kept by Statistics
Finland [http://www.stat.fi/tup/tilastotietokannat/index_
en.html] and were available separately for both sexes and
for each year of birth.Statistical analysis
BSID-II sum variables were tested for reliability by cal-
culating Cronbach’s alpha. Two groups defined by age
(16–30 years, over 30 years) or by gender were com-
pared for differences in neurocognitive development by
using Student’s t test or Mann–Whitney U test, as ap-
propriate. In order to study differences between the de-
velopmental ages and the results of BSID-II mental and
motor scales after the follow-up period, the paired-
sample t test was used.Reference Focus of test
[31] Motor and mental skills
ears) [20, 24] Comprehension of instructions
Oromotor sequences
Repetition of nonsense words
gns [22, 32] Test of corpus callosum functions
[23] Test of cerebellar functions
[25] The basic and functional mobility
Fig. 1 Survival of 41 subjects with SD. Kaplan-Meier survival analysis
and log-rank statistics were used to compare the age at death
(dotted line) and matched life expectancy at birth (solid line).
Log-rank analysis of the significance of the difference, p = 0.00005
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tasks were used to classify the subjects into three groups.
Subjects with no deficits, those with mild to moderate
deficits, and those with severe deficits were defined by
comparison with the reference values of each test [20,
23–25]. The statistical analyses were conducted using
Statistical Package for Social Sciences (SPSS) 20.0 (IBM
Corporation, New York, NY, USA) for Windows.
Results and discussion
Analysis of the participants in the baseline study and the
follow-up
Twenty-four of the 41 SD patients in the baseline study
[18] could be recruited to the follow-up study. The
participants, the non-participants, and the deceased
patients differed at baseline visit in age and mental and
motor developmental ages (Table 2). Further analysis
revealed that the eight deceased subjects differed signi-
ficantly from the 24 participants and from the six
non-participants (Mann–Whitney U test). At baseline,
the deceased subjects were older and their mental and
motor developmental ages were lower than those of the
participants and non-participants. The participants and
non-participants did not differ from each other.
The 41 patients with SD who had participated in the
baseline study were included in a survival analysis. The
analysis showed excess mortality among patients with
SD after the age of 30 years (Fig. 1). No difference was
noted between the genders (mean survival 57.2 years for
women, 59.0 years for men; p = 0.88, log-rank analysis).
Interestingly, four out of the eight deceased persons had
died at the age of 27 years (range, 20–40 years) younger
than expected, while four subjects had died 7 years
(range, −1–9 years) older than expected. There are no
previous studies on mortality of SD patients, and hence,
it is not known whether such subgroups are true. Any-
how, these two groups did not differ with respect to
mental developmental age (p = 0.69, Mann–Whitney U
test) or motor developmental age (p = 0.89) at the base-
line visit. All the eight deceased persons had epilepsy
during life, but unfortunately, we could not find out
whether epilepsy was the cause of death. Patients with
SD live longer than those with aspartylglucosaminuria
(AGU), another lysosomal storage disorder belonging toTable 2 Comparison of participants and non-participants
Participants Deceased Non-participants
N 24 8 6
Age, years 19.0 (1–51) 49.5 (28–62) 19.0 (1–62)
Mental DA, months 18.5 (6–41) 8.0 (1–15) 19.0 (8–26)
Motor DA, months 12.0 (2–38) 5.0 (2–11) 12.0 (7–21)
Values are medians (ranges)
DA developmental agethe Finnish disease heritage. On average, women with
AGU live to 40 years and men to 35 years [26].
Changes in motor and cognitive skills during the 13-year
follow-up
The median age of the 24 SD patients was 34 years
(range, 16–65 years) at the follow-up visit. The rate of
change in motor and mental developmental age was
calculated for each patient (Fig. 2). Between the baseline
study and the follow-up study, the change in motor de-
velopmental age (Fig. 2a) was positive till the age of 20
years in most patients, but after that age, motor skills
declined. There was no correlation between the rate of
change in motor developmental age and the chrono-
logical age (Pearson r = −0.395, p = 0.056). There was an
increase in mental developmental age in most patients
till their late thirties (Fig. 2b), but beyond that, there was
no further change. Indeed, there was an inverse correl-
ation between the rate of change in mental develop-
mental age and the chronological age (Pearson r = −0.481,
p = 0.017). Finally, there was a correlation between the
rate of change in mental developmental age and that in
motor developmental age (Pearson r = 0.685, p = 0.0002).
Neurocognitive deficits develop in childhood [7], but
the children acquire mental and motor skills till their
teens. The baseline study [18] has suggested that several
neurodevelopmental periods can be outlined in the clin-
ical progression of SD. The first period includes a nor-
mal fetal development as well as the first months after
birth, but muscular hypotonia, a delayed motor develop-
ment, and ataxia then emerge during the first year of
life. In the second period, slow development continues
until puberty. Severe ataxia is evident in childhood but
disappears between ages of 10 and 15 years. The present
Fig. 2 Rate of change in developmental age during the 13-year follow-up. The rate of change in motor (a) or mental (b) developmental age was
calculated per year of follow-up. Data at the baseline visit were obtained from [7]. Values are plotted at the midpoint between the age at baseline
and that at the follow-up visit
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tinues till twenties in spite of arising athetosis and spas-
ticity, and mental development continues till thirties.
The slowly progressive decline in motor abilities starts
after mid-thirties, while mental abilities seem to remain
constant till early sixties. Three neurocognitive periods
have been described in AGU, another lysosomal storage
disease belonging to the Finnish disease heritage [27]. In
AGU, a period of positive development in childhood is
followed by a gradual loss of skills in the teens and a
rapid decline in the twenties, which progression is more
severe than that in SD. The phenotype of AGU is less
variable than that in SD and, furthermore, resembles
more the conventional phenotype of SD [27]. Brain MRI
findings of AGU differ from those of SD as the thalami
are affected in AGU [28], while corpus callosum hypo-
plasia, dysmyelination, and cerebral and cerebellar atro-
phy are constant findings with SD [16].
Neurological features at the follow-up visit
Neurological evaluation revealed that motor functions
were severely affected. Eleven patients were able to walk
independently, but all of them had problems in coordin-
ation. Seven patients used a walking aid, and six patients
(severe phenotype, five; conventional phenotype, one)
were non-ambulatory. The non-ambulatory patients
were able to make stepping movements and to sit with
support. All patients had spastic lower limbs, and the
patellar reflexes were abnormally brisk. They also had
severe planovalgus, and Achilles reflex was absent.
Babinski sign was positive in ten cases.Twenty-three patients were able to use a partial thumb
opposition to grasp an object, and some of them also
used the pads of fingertips in grasping or holding a pen.
None of the patients could draw a circle or trace de-
signs, but two patients could copy a plus sign.
Dynamic cerebellar tests showed severe deficits in
motor sequencing and timing, but none of the patients
had ataxia, whereas mild to moderate athetosis was
present in 22 patients and two had severe athetosis since
the teens. Indeed, ataxia impaired fine motor skills in
childhood, but in adults, ataxia was replaced by athe-
tosis. Nystagmus was not observed, but all patients had
a moderate to severe strabismus.
Twelve patients had a history of epileptic seizures, but
EEG was available only from four patients. Based on
case histories, both primary and secondary generalized
epilepsies were assumed. Eight patients were on mono-
therapy, while the remaining four were on polytherapy.
In addition, three patients presented with startle-type re-
action to auditory stimulus. The median age at onset of
epilepsy was 29 years, and the patients with epilepsy
were significantly older than those without (p = 0.007).
An analysis of 121 patients with AGU has shown that 28
% of the adults but only 2 % of the children have epilep-
tic seizures [29, 30]. These figures suggest that SD and
AGU differ from each other in the onset of epilepsy.
Comparison of the clinical features at baseline [7, 18]
and at the follow-up visit suggested that spasticity
becomes more obvious with age especially in severely
disabled SD patients. Severe motor handicap is typical
for the conventional phenotype as well as the severe
Table 3 Frequency and severity of deficits in language and fine

















Finger to thumb 1 1 22
Toe tapping 8 4 12
Pegboard task 0 9 15
Bead threading 3 4 17
TUG test 2 8 14
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at baseline had learned to walk, and in the follow-up
examination, a similar proportion of patients were am-
bulatory. Dysmyelination of the CNS probably explains
the decline in motor and mental skills. The dysmyelina-
tion is expressed as homogeneous or periventricular
white matter disease in most patients and as thin corpus
callosum in all patients [16].
Neurocognitive functions at the follow-up visit
The receptive verbal skills were better than speech pro-
duction (p = 0.003; related samples Wilcoxon signed-
rank test), e.g., the patients were able to perform tasksFig. 3 Developmental age as a function of chronological age in 24 patient
tasks (a) or the mental tasks (b) of BSID-IIthat demand comprehension of instructions. All the
patients were able to vocalize a single sound, and the
patients with the conventional phenotype were able to
use at least two words appropriately, while patients with
the severe phenotype could not imitate words.
Concentration skills varied markedly among the
patients. Compared to the results of healthy children of
the age of 3.5 years described in the test manual of
BSID-II, visual tracking and visual attention tasks were
performed well, as well as tasks that demanded eye-
hand coordination (e.g., use of a spoon or comb). Tasks
related to visuospatial reasoning revealed cognitive
deficits in all patients and visuomotor performance was
slow. All patients recognized familiar faces and voices
and responded to a smile and showed emotional states
either verbally or non-verbally. Talkative patients were
able to remember songs and phraseologies and to learn
new ones. Most of the patients who could speak had
dysarthria or dyspraxia, but none of the patients had
aphasia. The caregivers described that the patients
learned daily routines and could keep short instructions
in mind. Patients could not perform the subtests of
PANESS. Performance in the dynamic cerebellar tests,
verbal tasks of NEPSY, and the TUG test is described in
Table 3.
The median age of 30 years was used to define two
groups. The younger group performed better in almost
every task of the mental scale. Significant differences
were found in constructive skills (p = 0.026), basic
counting (p = 0.016), and immediate visual recognition
(p = 0.026). No differences were detected in visual atten-
tion and interactive skills between the two groups.s with SD. Developmental age was determined by using the motor
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and the maximal mental developmental age was 42
months among the 24 SD patients. The developmental
ages of four subjects (age range, 16–34 years) were sig-
nificantly lower than those of other patients with a simi-
lar age. These four patients presented with the severe
phenotype of SD, and they were compound heterozy-
gotes harboring the R39C mutation only in one allele.
There was a significant inverse correlation between the
motor developmental age and the chronological age
(Fig. 3a) and between the mental developmental age
and chronological age (Fig. 3b). Motor and mental de-
velopmental ages at the follow-up visit correlated well
with each other (Pearson correlation coefficient r = 0.88,
p = 0.001), and this was the case also for the data ob-
tained at the baseline visit. The motor developmental
age at the follow-up visit was dependent on that at the
baseline visit, but not on age, sex, or baseline mental
developmental age. In a similar fashion, the mental
developmental age at the follow-up visit was dependent
on that at the baseline visit, but not on age, sex, or
motor developmental age at baseline.
Conclusions
In this study, we examined the course of clinical features
in patients with SD in a 13-year follow-up study. The
results of this follow-up study suggest better prognosis
in cognitive skills than previous cross-sectional studies.
Motor development continues till twenties and mental
development till thirties. The slowly progressive decline
in motor abilities starts after mid-thirties, while mental
abilities seem to remain constant till early sixties. The
motor handicap is severe, whereas the cognitive skills
related to verbal comprehension and interactive skills do
not deteriorate in adulthood. The early neurocognitive
development predicts the later course of motor and cog-
nitive development.
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